Assignee
SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD
CN·1 granted patent·6 pending applications·0 citations·filing 2022–2025
Top patents by PatentIndex Score
7 records- 0165US2024084304A1Composition and method for inhibiting angiotensinogen (agt) protein expressionSHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0261US12534726B2Composition and method for inhibiting angiotensinogen (AGT) protein expressionSHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2025·Granted Jan 27, 2026·0 cites·10 claims
- 0358US2025297250A1Composition and method for inhibiting expression of protein lpa(apo(a))SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0455US2025257356A1Composition and method for inhibiting expression of protein lpa(apo(a))SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2025·Application pending·0 cites
- 0553US2024376475A1Compositions and methods for inhibiting expression of angiopoietin-like 3 (angptl3) proteinSHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 0650US2025145999A1Compositions and methods for inhibiting expression of prekallikrein (pkk) proteinSHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 0749US2024271141A1Composition and method for inhibiting expression of hepatitis b virus (hbv)proteinSHANGHAI ARGO BIOPHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →